This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Big Pharma Stocks to Add to Your Portfolio in December
by Kinjel Shah
The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.
Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial
by Zacks Equity Research
Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.
4 Reasons Why Lilly is Up More Than 30% This Year So Far
by Zacks Equity Research
Eli Lilly's (LLY) stock is up 33.7% this year so far. Let us have a look at the reasons for the same.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FLQL
Corcept Initiates Phase III Study for Cushing's Syndrome
by Zacks Equity Research
Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $115.81 in the latest trading session, marking a +1.74% move from the prior day.
Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
by Zacks Equity Research
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
by Zacks Equity Research
Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.
Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug
by Zacks Equity Research
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.
Lilly Offers Updates on Progress of Headache Disorder Drugs
by Zacks Equity Research
Eli Lilly (LLY) files NDA with FDA for migraine candidate, lasmiditan. FDA grants Breakthrough Therapy status to Emgality for episodic cluster headache indication.
Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen receive EU approval for the label expansion of Cabometyx (cabozantinib) tablets as a monotherapy for HCC in adults.
AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study
by Zacks Equity Research
AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.
Merck Starts Rolling BLA Submission for Ebola Vaccine V920
by Zacks Equity Research
Merck (MRK) begins the rolling submission of a BLA for its investigational Ebola vaccine candidate V920 to the FDA.
Shire's Filing Accepted by FDA for Gattex's Label Expansion
by Zacks Equity Research
The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.
Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates
by Zacks Equity Research
Bayer (BAYRY) surpasses earnings and sales estimates in the third quarter of 2018 and reiterates outlook for 2018.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $113.20 in the latest trading session, marking a +0.88% move from the prior day.
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.
Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update
by Zacks Equity Research
Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.
Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag
by Zacks Equity Research
Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.
Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q3. Revenues fall on reduced contract revenues and also miss estimates.
Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
by Zacks Equity Research
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise
by Zacks Equity Research
Shares of Horizon Pharma (HZNP) rise almost 16%, owing to record quarterly sales during the third quarter of 2018.
Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.
AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the third quarter and maintains previously issued outlook for 2018. AstraZeneca's newer medicines sales rise 86% in the quarter.